[1] De-Siervi S,Cannito S, Turato C.Chronic liver disease:latest research in pathogenesis, detection and treatment. Int J Mol Sci,2023,24(13):10633.
[2] Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr, 2022, 41(4):990-1000.
[3] Wei S, Nguyen TT, Zhang Y, et al. Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front Endocrinol (Lausanne), 2023, 14:1185221.
[4] Topan MM, Sporea I, Dǎnilǎ M, et al. Association between dietary habits and sarcopenia in patients with liver cirrhosis. J Clin Med, 2023, 12(14):4693.
[5] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021, 397(10290):2212-2224.
[6] Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2020, 5(8):739-752.
[7] Miwa T, Francisque C, Tajirika S, et al. Impact of body fat accumulation on metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults. Hepatol Res, 2023, 53(8):691-700.
[8] Joo SK, Kim W. Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin Mol Hepatol, 2023, 29(Suppl):S68-S78.
[9] Tan EX. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism, 2022, 126:154911.
[10] Leung JC, Loong TC, Wei JL,et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology,2017, 65(1):54-64.
[11] Wei JL. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: apopulation study using proton-magnetic resonance spectroscopy. Am J Gastroenterol, 2015, 110(9):1306-1315.
[12] Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med, 2017, 377(21):2063-2072.
[13] Pan X, Han Y, Zou T, et al. Sarcopenia contributes to the progression of nonalcoholic fatty liver disease-related fibrosis: ameta-analysis. Dig Dis, 2018, 36(6):427-436.
[14] Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean sarcopenic obesity study. Hepatology, 2014, 59(5):1772-1778.
[15] Merli M, Lattanzi B, Aprile F. Sarcopenic obesity in fatty liver. Curr Opin Clin Nutr Metab Care, 2019, 22(3):185-190.
[16] Emhmed-Ali S, Nguyen MH. Sarcopenic obesity in non-alcoholic fatty liver disease—the union of two culprits. Life (Basel), 2021, 11(2):119.
[17] Petta S, Ciminnisi S, Di-Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2017, 45(4):510-518.
[18] Song W, Yoo SH, Jang J, et al. Association between sarcopenic obesity status and nonalcoholic fatty liver disease and fibrosis. Gut Liver, 2023, 17(1):130-138.
[19] Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers, 2018, 4(1):16.
[20] Tadokoro T, Morishita A, Himoto T, et al. Nutritional support for alcoholic liver disease. Nutrients, 2023, 15(6):1360.
[21] Traversy G, Chaput JP. Alcohol consumption and obesity: an update. Curr Obes Rep,2015, 4(1):122-130.
[22] Chiang DJ, McCullough AJ. The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis, 2014, 18(1):157-163.
[23] Huang DQ, Mathurin P, Cortez-Pinto H, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors.Nat Rev Gastroenterol Hepatol, 2023, 20(1):37-49.
[24] Sakamaki A, Yokoyama K, Koyama K, et al. Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis.PLoS One, 2020, 15(11):e0242582.
[25] Dasarathy J, McCullough AJ, Dasarathy S. Sarcopenia in alcoholic liver disease: clinical and molecular advances. Alcohol Clin Exp Res, 2017, 41(8):1419-1431.
[26] McClain CJ, Rios CD, Condon S,et al. Malnutrition and alcohol-associated hepatitis. Clin Liver Dis, 2021, 25(3):557-570.
[27] Boster JM, Saiman Y. Nutritional management of sarcopenia in chronic liver disease. Curr Treat Options Gastro, 2021, 19(3):509-523.
[28] Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis, 2012, 16(1):95-131.
[29] Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle, 2012, 3(4):225-237.
[30] Benjamin J, Shasthry V, Kaal CR,et al. Characterization of body composition and definition of sarcopenia in patients with alcoholic cirrhosis: a computed tomography based study. Liver Int, 2017, 37(11):1668-1674.
[31] Juakiem W, Torres DM, Harrison SA. Nutrition in cirrhosis and chronic liver disease. Clin Liver Dis, 2014, 18(1):179-190.
[32] Sundaram V, Jalan R, Ahn JC, et al. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. J Hepatol, 2018, 69(3):617-625.
[33] Ebadi M, Dunichand-Hoedl AR, Rider E, et al. Higher subcutaneous adipose tissue radiodensity is associated with increased mortality in patients with cirrhosis. JHEP Rep, 2022, 4(7):100495.
[34] Lai JC, Tandon P, Bernal W,et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the study of liver diseases. Hepatology, 2021, 74(3):1611-1644.
[35] Mazeaud S, Zupo R, Couret A, et al. Prevalence of sarcopenia in liver cirrhosis: asystematic review and meta-analysis.Clin Transl Gastroenterol, 2023, 14(7):e00584.
[36] Khan S, Benjamin J, Maiwall R, et al. Sarcopenia is the independent predictor of mortality in critically ill patients with cirrhosis. J Clin Transl Res, 2022, 8(3):200-208.
[37] Guo G, Li C, Hui Y, et al. Sarcopenia and frailty combined increases the risk of mortality in patients with decompensated cirrhosis.Ther Adv Chronic Dis, 2022, 13:20406223221109651.
[38] Nishikawa H, Enomoto H, Nishiguchi S, et al. Sarcopenic obesity in liver cirrhosis: possible mechanism and clinical impact. Int J Mol Sci, 2021, 22(4):1917.
[39] Feng H, Wang X, Zhao T, et al. Myopenic obesity determined by visceral fat area strongly predicts long-term mortality in cirrhosis. Clin Nutr, 2021, 40(4):1983-1989.
[40] Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle, 2016, 7(2):126-135.
[41] Eslamparast T, Montano-Loza AJ, Raman M, et al. Sarcopenic obesity in cirrhosis-the confluence of 2 prognostic titans. Liver Int, 2018, 38(10):1706-1717.
[42] Hara N, Iwasa M, Sugimoto R, et al. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. Intern Med, 2016, 55(8):863-870.
[43] Ha NB, Fan B, Shui AM, et al. CT-quantified sarcopenic visceral obesity is associated with poor transplant waitlist mortality in patients with cirrhosis. Liver Transpl, 2023, 29(5):476-484.
[44] Hegyi PJ, Soós A, Hegyi P, et al. Pre-transplant sarcopenic obesity worsens the survival after liver transplantation: ameta-analysis and a systematic review. Front Med (Lausanne), 2020, 7:599434.
[45] Kamo N, Kaido T, Hamaguchi Y, et al. Impact of sarcopenic obesity on outcomes in patients undergoing living donor liver transplantation. Clin Nutr, 2019, 38(5):2202-2209.
[46] Ha NB, Montano-Loza AJ, Carey EJ, et al. Sarcopenic visceral obesity is associated with increased post‐liver transplant mortality in acutely ill patients with cirrhosis. Am J Transplant, 2022, 22(9):2195-2202.
[47] Ali-Deeb A, Settmacher U, Fritsch J, et al. Sarcopenic obesity may predict worse liver regeneration after right graft living donor liver transplantation. Liver Transpl,2024,30(4):412-420.
[48] Li X, Huang X, Lei L,et al. Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis. Front Nutr, 2023, 10:1233973.
[49] Wang P, Wang S, Ma Y,et al. Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: ameta-analysis. Front Nutr, 2022, 9:921817.
[50] Lavender C, Perisetti A, Dranoff J, et al. Impact of sarcopenia and sarcopenic obesity on transplant-free survival in patients with hepatocellular carcinoma undergoing locoregional therapy. Gastroenterology, 2020, 158(6):S-1395.
[51] Kobayashi A, Kaido T, Hamaguchi Y, et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg, 2019, 269(5):924-931.
[52] Itoh S, Yoshizumi T, Kimura K, et al. Effect of sarcopenic obesity on outcomes of living-donor liver transplantation for hepatocellular carcinoma. Anticancer Res, 2016, 36(6):3029-3034.
[53] Lee O, Shin YC, Ryu Y, et al. Adverse effects of sarcopenic obesity on postoperative complications after major hepatectomy in patients with hilar cholangiocarcinoma. J Clin Med, 2022, 11(7):1860. |
